Candidemia: a nosocomial complication in adults with late-stage AIDS

Clin Infect Dis. 1998 May;26(5):1134-41. doi: 10.1086/520291.

Abstract

We retrospectively analyzed 13 episodes of candidemia observed between July 1990 and July 1995 in human immunodeficiency virus (HIV)-infected adults. Candidemia was nosocomially acquired by 11 patients, among whom nine had a central venous catheter (CVC). Twelve cases were of stage C2/C3 according to the 1993 classification of the Centers for Disease Control and Prevention. The median CD4+ cell count was 10/mm3 (range, 3-400/mm3). Causative species were Candida albicans in nine episodes and Candida glabrata and Candida krusei in two episodes each. Eleven episodes occurred in 11 patients who had previously received fluconazole (mean total dose, 7.4 g), including the four episodes caused by non-albicans species. Outcome did not differ according to the administered antifungal therapy. CVCs were removed from seven patients (78%). The overall mortality was 38%. Candidemia is a potentially lethal nosocomial complication during late-stage AIDS and can be due to C. albicans and non-albicans strains.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / microbiology
  • Adult
  • Aged
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Candida / classification
  • Candida / isolation & purification
  • Candidiasis / drug therapy
  • Candidiasis / epidemiology*
  • Candidiasis / microbiology
  • Catheterization, Central Venous / adverse effects
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Female
  • Fluconazole / administration & dosage
  • Fluconazole / therapeutic use
  • Fungemia / drug therapy
  • Fungemia / epidemiology*
  • Fungemia / microbiology
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors

Substances

  • Antifungal Agents
  • Amphotericin B
  • Fluconazole